This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Clinical features of neonatal jaundice

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

In addition to the obvious icteric discolouration of the neonate, other clinical features may include:

  • failure to thrive
  • poor feeding
  • other features of the underlying aetiology

NICE state that (1)

  • identify babies as being more likely to develop significant hyperbilirubinaemia if they have any of the following factors:

    • gestational age under 38 weeks
    • a previous sibling with neonatal jaundice requiring phototherapy
    • mother's intention to breastfeed exclusively
    • visible jaundice in the first 24 hours of life

  • in all babies:
    • check whether there are factors associated with an increased likelihood of developing significant hyperbilirubinaemia soon after birth
    • examine the baby for jaundice at every opportunity especially in the first 72 hours

  • when looking for jaundice (visual inspection):
    • examine the sclerae and gums, and press lightly on the skin to check for signs of jaundice in 'blanched' skin
    • do not rely on visual inspection alone to estimate the bilirubin level in a baby with suspected jaundice

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.